MedTrace Logo

1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.

NCT00345696 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2011-08-24

No results posted yet for this study

Summary

The purpose of this study is to determinate progression free survival after 9 months of treatment.

Conditions

Interventions

DRUG

Bevacizumab

5 mg/Kg intravenous, 90-60-30 minutes, every 2 weeks.

DRUG

Capecitabine

600 mg/m2, orally, every 12 hours, continuous.

DRUG

Oxaliplatine

85 mg/m2, intravenous, 2 hours infusion, every 2 weeks

Sponsors & Collaborators

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Unidad Integral de Investigación en Oncología S.L.

    lead OTHER

Principal Investigators

  • Cristina Grávalos, MD · Unidad Integral de Investigación en Oncología S.L.

  • Cristina Grávalos, MD · Hospital 12 de Octubre

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2008-10-31
Completion
2011-01-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00345696 on ClinicalTrials.gov